Galecto, Inc. is a clinical-stage biotechnology company based in Copenhagen, Denmark, focused on developing innovative therapeutic molecules aimed at addressing significant unmet medical needs in fibrosis, cancer, and inflammation. With a robust pipeline of candidates, Galecto leverages its proprietary galectin technology platform to target pathways involved in disease progression, positioning itself as a promising player in the biopharmaceutical sector. The company's commitment to advancing treatments demonstrates its potential for impactful contributions to patient care and growth in the biotechnology landscape.